Moderna’s chief information officer Brad Miller is 'retiring' in February, a company spokesperson confirmed to Endpoints News ...
Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback